Brief: Essex Bio-Technology's unit Receives Approval For Commercialisation Of Multi-Dose Sodium Hyaluronate Eye Drops From NMPA
Jan 9 (Reuters) - Essex Bio-Technology Ltd 1061.HK: UNIT RECEIVES APPROVAL FOR MULTI-DOSE SODIUM HYALURONATE EYE DROPS FROM NMPA RECEIVED APPROVAL FOR REGISTRATION & COMMERCIALISATION OF THE APPROVED PRODUCT Further company coverage: 1061.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Essex Bio-Technology
See all newsHong Kong's Essex Bio-Technology H1 revenue falls
Brief: Essex Bio-Technology Posts HY Profit Of HK$110.7 MLN
Brief: Essex Bio-Technology Expects 10% Revenue And 30% Profit Decrease For HY
Brief: Shanghai Henlius Biotech Says Phase 3 Study Of HLX04-O For WAMD Meets Primary Endpoint
Brief: Essex Bio-Technology Posts Final Dividend Of HK$0.07 Per Share